Felipe F Quezada-Diaz1, Irbaz Hameed1, Alexa von Mueffling1, Erin E Salo-Mullen2, Alice Catalano1, J Joshua Smith3, Martin R Weiser1, Julio Garcia-Aguilar1, Zsofia K Stadler2, Jose G Guillem4. 1. Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: guillemj@mskcc.org.
Abstract
BACKGROUND: Because of increased risk of metachronous colorectal cancer (CRC), all patients with Lynch syndrome (LS) are offered a total colectomy. However, because metachronous CRC rate by mismatch repair (MMR) gene is uncertain, and total colectomy negatively impacts quality of life, it remains unclear whether segmental resection is indicated for lower penetrance MMR genes. We evaluated metachronous CRC incidence according to MMR gene in LS patients who underwent a segmental colectomy. STUDY DESIGN: Single-center, retrospective cohort study in patients with an earlier colectomy for CRC and an MMR germline mutation in MLH1, MSH2, MSH6, or PMS2 followed prospectively in a hereditary CRC family registry. All patients underwent surveillance colonoscopy. Metachronous CRC was defined as one detected more than 1 year after index resection. Primary end point was cumulative incidence of metachronous CRC overall and by MMR gene. RESULTS: One hundred and ten patients were included: 35 with MLH1 likely pathogenic/pathogenic (LP/P) variants (32%), 42 MSH2 (38%), 20 MSH6 (18%), and 13 PMS2 (12%). Median follow-up 4.26 years (range 0.53 to 19.92 years). Overall, metachronous CRC developed in 22 patients (20%). At 10-year follow-up, incidence was 12% (95% CI 6% to 23%), with no metachronous CRC detected in patients with a PMS2 or MSH6 LP/P variant. CONCLUSIONS: After index segmental resection, metachronous CRC is less likely to develop in LS patients with MSH6 or PMS2 LP/P variant than in MLH1 or MSH2 carriers. Our data support segmental resection and long-term colonoscopic surveillance rather than total colectomy in carefully selected, well-informed LS patients with MSH6 or PMS2 LP/P variant.
BACKGROUND: Because of increased risk of metachronous colorectal cancer (CRC), all patients with Lynch syndrome (LS) are offered a total colectomy. However, because metachronous CRC rate by mismatch repair (MMR) gene is uncertain, and total colectomy negatively impacts quality of life, it remains unclear whether segmental resection is indicated for lower penetrance MMR genes. We evaluated metachronous CRC incidence according to MMR gene in LS patients who underwent a segmental colectomy. STUDY DESIGN: Single-center, retrospective cohort study in patients with an earlier colectomy for CRC and an MMR germline mutation in MLH1, MSH2, MSH6, or PMS2 followed prospectively in a hereditary CRC family registry. All patients underwent surveillance colonoscopy. Metachronous CRC was defined as one detected more than 1 year after index resection. Primary end point was cumulative incidence of metachronous CRC overall and by MMR gene. RESULTS: One hundred and ten patients were included: 35 with MLH1 likely pathogenic/pathogenic (LP/P) variants (32%), 42 MSH2 (38%), 20 MSH6 (18%), and 13 PMS2 (12%). Median follow-up 4.26 years (range 0.53 to 19.92 years). Overall, metachronous CRC developed in 22 patients (20%). At 10-year follow-up, incidence was 12% (95% CI 6% to 23%), with no metachronous CRC detected in patients with a PMS2 or MSH6 LP/P variant. CONCLUSIONS: After index segmental resection, metachronous CRC is less likely to develop in LS patients with MSH6 or PMS2 LP/P variant than in MLH1 or MSH2 carriers. Our data support segmental resection and long-term colonoscopic surveillance rather than total colectomy in carefully selected, well-informed LS patients with MSH6 or PMS2 LP/P variant.
Authors: Hans F A Vasen; Mohamed Abdirahman; Richard Brohet; Alexandra M J Langers; Jan H Kleibeuker; Mariette van Kouwen; Jan Jacob Koornstra; Henk Boot; Annemieke Cats; Evelien Dekker; Silvia Sanduleanu; Jan-Werner Poley; James C H Hardwick; Wouter H de Vos Tot Nederveen Cappel; Andrea E van der Meulen-de Jong; T Gie Tan; Maarten A J M Jacobs; Faig Lall A Mohamed; Sijbrand Y de Boer; Paul C van de Meeberg; Marie-Louise Verhulst; Jan M Salemans; Nico van Bentem; B Dik Westerveld; Juda Vecht; Fokko M Nagengast Journal: Gastroenterology Date: 2010-03-02 Impact factor: 22.682
Authors: Susan Parry; Aung Ko Win; Bryan Parry; Finlay A Macrae; Lyle C Gurrin; James M Church; John A Baron; Graham G Giles; Barbara A Leggett; Ingrid Winship; Lara Lipton; Graeme P Young; Joanne P Young; Caroline J Lodge; Melissa C Southey; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins Journal: Gut Date: 2010-12-30 Impact factor: 23.059
Authors: Sanne W ten Broeke; Richard M Brohet; Carli M Tops; Heleen M van der Klift; Mary E Velthuizen; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G W Letteboer; Fred H Menko; Annika Lindblom; Arjen R Mensenkamp; Pal Moller; Theo A van Os; Nils Rahner; Bert J W Redeker; Rolf H Sijmons; Liesbeth Spruijt; Manon Suerink; Yvonne J Vos; Anja Wagner; Frederik J Hes; Hans F Vasen; Maartje Nielsen; Juul T Wijnen Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Aung Ko Win; Susan Parry; Bryan Parry; Matthew F Kalady; Finlay A Macrae; Dennis J Ahnen; Graeme P Young; Lara Lipton; Ingrid Winship; Alex Boussioutas; Joanne P Young; Daniel D Buchanan; Julie Arnold; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins Journal: Ann Surg Oncol Date: 2013-01-29 Impact factor: 5.344
Authors: Leigha Senter; Mark Clendenning; Kaisa Sotamaa; Heather Hampel; Jane Green; John D Potter; Annika Lindblom; Kristina Lagerstedt; Stephen N Thibodeau; Noralane M Lindor; Joanne Young; Ingrid Winship; James G Dowty; Darren M White; John L Hopper; Laura Baglietto; Mark A Jenkins; Albert de la Chapelle Journal: Gastroenterology Date: 2008-05-02 Impact factor: 22.682
Authors: Neil A J Ryan; Julie Morris; Kate Green; Fiona Lalloo; Emma R Woodward; James Hill; Emma J Crosbie; D Gareth Evans Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Mev Dominguez-Valentin; Julian R Sampson; Toni T Seppälä; Sanne W Ten Broeke; John-Paul Plazzer; Sigve Nakken; Christoph Engel; Stefan Aretz; Mark A Jenkins; Lone Sunde; Inge Bernstein; Gabriel Capella; Francesc Balaguer; Huw Thomas; D Gareth Evans; John Burn; Marc Greenblatt; Eivind Hovig; Wouter H de Vos Tot Nederveen Cappel; Rolf H Sijmons; Lucio Bertario; Maria Grazia Tibiletti; Giulia Martina Cavestro; Annika Lindblom; Adriana Della Valle; Francisco Lopez-Köstner; Nathan Gluck; Lior H Katz; Karl Heinimann; Carlos A Vaccaro; Reinhard Büttner; Heike Görgens; Elke Holinski-Feder; Monika Morak; Stefanie Holzapfel; Robert Hüneburg; Magnus von Knebel Doeberitz; Markus Loeffler; Nils Rahner; Hans K Schackert; Verena Steinke-Lange; Wolff Schmiegel; Deepak Vangala; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; John L Hopper; Aung Ko Win; Robert W Haile; Noralane M Lindor; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Jane C Figueiredo; Stephen N Thibodeau; Karin Wadt; Christina Therkildsen; Henrik Okkels; Zohreh Ketabi; Leticia Moreira; Ariadna Sánchez; Miquel Serra-Burriel; Marta Pineda; Matilde Navarro; Ignacio Blanco; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Oliver G Denton; Ian M Frayling; Einar Andreas Rødland; Hans Vasen; Miriam Mints; Florencia Neffa; Patricia Esperon; Karin Alvarez; Revital Kariv; Guy Rosner; Tamara Alejandra Pinero; María Laura Gonzalez; Pablo Kalfayan; Douglas Tjandra; Ingrid M Winship; Finlay Macrae; Gabriela Möslein; Jukka-Pekka Mecklin; Maartje Nielsen; Pål Møller Journal: Genet Med Date: 2019-07-24 Impact factor: 8.822